Castle Biosciences INC

Castle Biosciences reported strong second quarter 2026 results, with revenue increasing to $103.5 million and full-year revenue guidance raised to $365-375 million.

Castle Biosciences stockholders re-elected three Class I directors and ratified the appointment of KPMG LLP as the independent auditor.

Castle Biosciences reported first quarter 2026 results, with revenue of $83.7 million and an increase in total test reports for core drivers by 36%, leading to an upward revision of full-year revenue guidance.

Castle Biosciences reported strong fourth quarter and full-year 2025 results, exceeding revenue guidance with $344 million and significant growth in core test reports.

Castle Biosciences announced preliminary unaudited Q4 and full-year 2025 results, with total revenue exceeding $340 million, above previous guidance, driven by strong growth in core diagnostic tests.

Castle Biosciences reported mixed third-quarter 2025 financial results, including a revenue decline, but raised its full-year 2025 revenue guidance and launched a new atopic dermatitis test.

Castle Biosciences reports Q2 2026 results with revenue growth driven by non-dermatologic tests, though net loss widens.

Castle Biosciences reported a net loss of $0.5 million in Q3 2025, a significant decline from a $2.3 million net income in Q3 2024, primarily due to a decrease in dermatologic test revenue and increased operating expenses, despite strong growth in non-dermatologic tests.

Castle Biosciences reported a net loss for the six months ended June 30, 2025, driven by the discontinuation of its IDgenetix test and loss of Medicare coverage for DecisionDx-SCC, despite overall revenue growth.

Castle Biosciences saw a revenue increase in Q1 2025, but a larger net loss due to the discontinuation of its IDgenetix test and related amortization expenses.

Castle Biosciences reports a strong third quarter in 2024, achieving profitability with significant revenue growth driven by both dermatologic and non-dermatologic testing segments.

Castle Biosciences experienced a significant increase in revenue and a return to profitability in the second quarter of 2024, driven by strong performance in both dermatologic and non-dermatologic testing segments.

Castle Biosciences reported a net loss of $24.2 million in 2025, a significant reversal from the prior year's profit, despite a 3.7% increase in total net revenues driven by non-dermatologic tests.

Castle Biosciences reported a return to profitability and a 51% revenue increase for the fiscal year 2024, fueled by its dermatology and gastroenterology tests, though future results face uncertainty due to an impending Medicare non-coverage decision for its DecisionDx-SCC test.

Castle Biosciences' 2023 annual report showcases significant revenue growth, driven by its dermatologic testing franchise and strategic acquisitions, while also detailing ongoing challenges and future pipeline developments.

Derek J Maetzold, Pres. & Chief Exec. Officer and a Director of Castle Biosciences Inc, sold 9,836 shares of common stock on July 27, 2026.

Derek J Maetzold, Pres. & Chief Exec. Officer and a Director of Castle Biosciences Inc, sold 4,172 shares of common stock on July 14, 2026 for $22.92 per share.

Derek J. Maetzold, President & CEO of Castle Biosciences Inc., reported transactions involving the sale of common stock under a pre-arranged trading plan.

Castle Biosciences COO Kristen M. Oelschlager reported the sale of 8,186 shares of common stock for approximately $24.40 per share and 400 shares for approximately $24.78 per share, executed under a Rule 10b5-1 trading plan.

Castle Biosciences Chief Operating Officer Kristen M. Oelschlager reported a sale of common stock executed under a pre-arranged trading plan.

CEO Derek Maetzold sold shares of Castle Biosciences common stock on June 15, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Castle Biosciences invites stockholders to its 2026 Annual Meeting on May 28, 2026, to vote on director elections, auditor ratification, executive compensation, and director compensation policy.

Castle Biosciences, Inc. has filed a definitive proxy statement with the SEC.

Castle Biosciences announces a 51% revenue increase for 2024, exceeding guidance, and invites stockholders to the 2025 Annual Meeting.

Castle Biosciences issues a letter to stockholders highlighting changes made to executive compensation in response to stockholder feedback, urging a vote in favor of the Say-on-Pay proposal at the upcoming Annual Meeting.

Castle Biosciences, Inc. has filed a definitive proxy statement with the SEC.

Castle Biosciences' 2024 Proxy Statement highlights the company's strong 2023 performance and outlines its strategy for continued growth and value creation.

Portolan Capital Management and George McCabe have filed an amendment reporting a 4.45% beneficial ownership stake in Castle Biosciences, Inc.

RTW Investments, LP and Roderick Wong have reported a beneficial ownership of 9.3% in Castle Biosciences, Inc., totaling 2,758,335 shares as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Castle Biosciences Inc. due to an internal corporate realignment.

RTW Investments, LP and Roderick Wong, M.D. have disclosed a 7.2% beneficial ownership stake in Castle Biosciences, Inc. as of December 31, 2025.

Dimensional Fund Advisors LP has disclosed a 3.9% passive ownership stake in Castle Biosciences Inc. common stock as of December 31, 2025.

Dimensional Fund Advisors LP has reported a 5.1% beneficial ownership stake in Castle Biosciences Inc. common stock, held in the ordinary course of business.